Translator Disclaimer
4 March 2010 Photoselective vaporization of the prostate: outcomes and adverse events of 220 consecutive patients
Author Affiliations +
Proceedings Volume 7548, Photonic Therapeutics and Diagnostics VI; 754817 (2010) https://doi.org/10.1117/12.841402
Event: SPIE BiOS, 2010, San Francisco, California, United States
Abstract
Purpose: To evaluate the short term outcomes of 220 consecutive patients who underwent the 532 nm KTP photoselective vaporization of the prostate (PVP) procedure and to evaluate and categorize the complications of the procedure. Materials and Methods: A total of 220 patients with symptomatic benign prostatic obstruction were treated with KTP photoselective vaporization of the prostate. Evaluation measures included the AUA Symptom Score (AUASS)/Quality of Life Score (QOL), peak urinary flow rate (Qmax), post void residual urine (PVR) and adverse events. Results: Symptoms were evaluated at 3 months and adverse events at 1 and 3 months. 181 patients returned for their 1 month visit and 152 returned for their 3 month visit. The American Urological Association Symptom Score (AUASS) decreased from 21.8 to 6.7. The Quality of Life Score (QOL) decreased from 3.8 to 0.7. The peak urinary flow rate (Qmax) increased from 10.7 cc/sec to 22.7 cc/sec. And the post void residual urine (PVR) decreased from 262 cc to 105 cc. Most common adverse events lasting more than 10 days were mild hematuria in 45%, dysuria in 32%, and urgency/frequency in31%. Conclusion: These results confirm that photoselective vaporization of the prostate (PVP) is a safe and effective therapy for benign prostatic obstruction. However, there is frequent, but mild, hematuria and irritative voiding symptoms during the early postoperative period.
© (2010) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
C. Robson and E. J. Mueller "Photoselective vaporization of the prostate: outcomes and adverse events of 220 consecutive patients", Proc. SPIE 7548, Photonic Therapeutics and Diagnostics VI, 754817 (4 March 2010); https://doi.org/10.1117/12.841402
PROCEEDINGS
5 PAGES


SHARE
Advertisement
Advertisement
Back to Top